Payment overview · 2025
General Payments
$5,807.02
18 reported records · 6 companies
Healthcare provider profile · identity verified
Ankit Patel, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CHELMSFORD, MA · NPI 1083096317
Verified facts
What the public records show
CMS Open Payments records show Ankit Patel, M.D. received $5,807.02 in general payments during 2025 across 18 reported records.
ACADIA Pharmaceuticals Inc accounted for 96.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nuplazid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Vraylar by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nuplazid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Myrbetriq by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $5,621.39 | 96.8% | 10 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $80.01 | 1.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.80 | 0.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.08 | 0.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.02 | 0.4% | 1 | 2025 |
| Lucid Diagnostics Inc. | Unresolved — no canonical attribution shown | $18.72 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,100.00 | 3 |
| Food and Beverage | $536.22 | 14 |
| Travel and Lodging | $170.80 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $5,621.39 | 10 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $80.01 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.80 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.80 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $28.08 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1121 | 129 |
| Trazodone Hcl | Trazodone Hcl | 862 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 770 | 76 |
| Furosemide | Furosemide | 740 | 87 |
| Eliquis | Apixaban | 724 | 63 |
| Gabapentin | Gabapentin | 598 | 79 |
| Sertraline Hcl | Sertraline Hcl | 534 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 514 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 440 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 436 | 66 |
| Metformin Hcl | Metformin Hcl | 427 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 418 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 393 | 39 |
| Mirtazapine | Mirtazapine | 390 | 44 |
| Lisinopril | Lisinopril | 368 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 344 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 265 | 26 |
| Famotidine | Famotidine | 263 | 28 |
| Divalproex Sodium | Divalproex Sodium | 255 | 31 |
| Losartan Potassium | Losartan Potassium | 229 | 27 |
| Donepezil Hcl | Donepezil Hcl | 226 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 222 | 22 |
| Potassium Chloride | Potassium Chloride | 218 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 192 | 19 |
| Allopurinol | Allopurinol | 178 | 23 |
| Simvastatin | Simvastatin | 167 | 17 |
| Omeprazole | Omeprazole | 164 | 27 |
| Risperidone | Risperidone | 156 | 13 |
| Xarelto | Rivaroxaban | 151 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 145 | 18 |
| Olanzapine | Olanzapine | 144 | 20 |
| Baclofen | Baclofen | 132 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 122 | suppressed |
| Levetiracetam | Levetiracetam | 121 | 25 |
| Torsemide | Torsemide | 121 | 17 |
| Carvedilol | Carvedilol | 118 | 12 |
| Finasteride | Finasteride | 108 | 21 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 96 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 92 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 92 | suppressed |
| Spironolactone | Spironolactone | 92 | 22 |
| Memantine Hcl | Memantine Hcl | 90 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 88 | 22 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 87 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 85 | suppressed |
| Lamotrigine | Lamotrigine | 84 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 80 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 78 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 77 | 11 |
| Midodrine Hcl | Midodrine Hcl | 76 | 14 |
| Aripiprazole | Aripiprazole | 74 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 65 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 62 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 62 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 61 | suppressed |
| Glipizide Er | Glipizide | 60 | suppressed |
| Myrbetriq | Mirabegron | 60 | suppressed |
| Glipizide | Glipizide | 57 | suppressed |
| Prednisone | Prednisone | 57 | 28 |
| Valsartan | Valsartan | 56 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 55 | suppressed |
| Humalog | Insulin Lispro | 53 | 15 |
| Trulicity | Dulaglutide | 52 | 13 |
| Ranolazine Er | Ranolazine | 51 | suppressed |
| Atenolol | Atenolol | 50 | suppressed |
| Jardiance | Empagliflozin | 50 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 49 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 48 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 48 | suppressed |
| Latanoprost | Latanoprost | 47 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 47 | 12 |
| Memantine Hcl Er | Memantine Hcl | 46 | suppressed |
| Sulfasalazine | Sulfasalazine | 46 | suppressed |
| Ezetimibe | Ezetimibe | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 22 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 43 | 33 |
| Raloxifene Hcl | Raloxifene Hcl | 43 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 41 | 24 |
| Digoxin | Digoxin | 41 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 41 | 12 |
| Folic Acid | Folic Acid | 40 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 37 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Verapamil Er | Verapamil Hcl | 36 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Colchicine | Colchicine | 33 | suppressed |
| Lorazepam | Lorazepam | 33 | 18 |
| Methotrexate | Methotrexate Sodium | 32 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 31 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 15 |
| Naproxen | Naproxen | 30 | suppressed |
| Methimazole | Methimazole | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 18 |
| Celecoxib | Celecoxib | 27 | suppressed |
| Haloperidol | Haloperidol | 27 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 26 | suppressed |
| Carbamazepine | Carbamazepine | 25 | suppressed |
| Clozapine | Clozapine | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | 13 |
| Acyclovir | Acyclovir | 23 | suppressed |
| Clonazepam | Clonazepam | 23 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 23 | suppressed |
| Novolog | Insulin Aspart | 23 | suppressed |
| Nyamyc | Nystatin | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 20 |
| Irbesartan | Irbesartan | 22 | suppressed |
| Levemir | Insulin Detemir | 21 | suppressed |
| Oxycontin | Oxycodone Hcl | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Calcitriol | Calcitriol | 20 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 16 |
| Nuplazid | Pimavanserin Tartrate | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Mesalamine | Mesalamine | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Trifluoperazine Hcl | Trifluoperazine Hcl | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 13 |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Erythromycin | Erythromycin Base | 17 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 16 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 16 | suppressed |
| Trimethoprim | Trimethoprim | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 15 | suppressed |
| Soaanz | Torsemide | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 14 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Nystatin | Nystatin | 12 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Leflunomide | Leflunomide | 11 | suppressed |
| Permethrin | Permethrin | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,807.02 · 18 records | ACADIA Pharmaceuticals Inc | Cologuard Collection Kit, NUPLAZID, QULIPTA, REXULTI, UBRELVY, Veozah | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nuplazid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error